BioSpace News Archive

Business

Septerna Will Take $100M to Unlock Previously Inaccessible GPCRs

Led by Third Rock Ventures, the financing will support Septerna in tapping into new therapeutic areas for G protein-coupled receptor (GPCR) drug targets.

January 27, 2022
·
2 min read
·
Hannah Chudleigh
Business

Enzyvant and Adaptimmune Snag Experienced Chief Commercial Officers

After guiding the commercial rollout of embattled Alzheimer’s drug Aduhelm for Biogen, Johanna Rossell has departed the company for a leadership role at Enzyvant.

January 27, 2022
·
2 min read
·
Alex Keown
Biotech Bay

Research Roundup: How COVID-19 Vaccines Train T Cells and More Research News

Although most of the news about the effectiveness and endurance of COVID-19 vaccines has focused on antibody titers, not as much has been reported on their effect on other parts of the immune system that offer longer-term protection, such as T cells. For that and more, continue reading.

January 27, 2022
·
6 min read
·
Mark Terry
Drug Development

Viking X-ALD Study Paused Over Conflicting Phase Interpretations

The FDA is calling the study a phase II trial and says the company must run a rodent genotoxicity study before it can continue.

January 27, 2022
·
2 min read
·
Jill Gartz
Pharm Country

BioSpace Movers & Shakers, Jan. 28

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

January 27, 2022
·
8 min read
·
Alex Keown
Drug Development

Lithium-Sparing Alzheimer’s Therapy has Strong Benefit-to-Risk Profile

Alzamend Neuro is looking to commence a Phase II multiple ascending dose study of lead compound, AL001, in Alzheimer’s disease during the second quarter of this year.

January 27, 2022
·
5 min read
·
Gail Dutton
Drug Development

Studies Forge On as Omicron Surges and More COVID-19 News

In the last two years, the sheer volume of scientific research focused on COVID-19 has been astounding—thousands of clinical studies, dozens of vaccines and new compounds, and hundreds of approved drugs tested for efficacy against COVID-19.

January 27, 2022
·
5 min read
·
Mark Terry
Drug Development

Merck’s Cancer Blockbuster Keytruda Might Treat HIV Too

The researchers believe Keytruda and possibly other anti-PD-1 checkpoint inhibitors might help the immune system track the last signs of HIV while also preventing HIV’s ability to hide.

January 27, 2022
·
3 min read
·
Mark Terry
Policy

Report Shows Americans Pay More for Drugs Than the Countries Making Them

Americans pay the highest drug prices in the world while importing drugs for lower prices from other countries has been locked down on a personal level and labeled as “unsafe.”

January 27, 2022
·
4 min read
·
Kate Goodwin
Drug Development

TG Therapeutics Combo Cancer Therapy Hit with Partial Hold

The studies are of the U2 combination Ukoniq (umbralisib) and ublituximab for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).

January 27, 2022
·
3 min read
·
Mark Terry